Organization
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
12 clinical trials
1 abstract
Abstract
Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.Org: Affiliated Cancer Hosiptal of Zhengzhou University, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,
Clinical trial
A Phase I, Open-Label, Multicenter, Dose-Escalation And Cohort-Expansion Study Of IMM47 In Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-26
Clinical trial
IMM2510, a Multi-Center, Open-Label, Dose Escalation and Cohort Expansion Phase I Clinical Study for Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1 Study to Evaluate IMM27M Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced, Metastatic Solid TumorStatus: Recruiting, Estimated PCD: 2023-08-30
Clinical trial
A Phase Ib/IIa Clinical Study of IMM0306 fo r Injection in Combination With Lenalidomide for the Treatment of Relapsed/Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Cell Non-Hodgkin's LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDSStatus: Recruiting, Estimated PCD: 2024-02-05
Clinical trial
A Phase 1 Clinical Study to Evaluate IMM01 Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Refractory or Recurrent Hematologic MalignancyStatus: Terminated, Estimated PCD: 2022-10-26
Clinical trial
A Phase 1b/2 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and LymphomasStatus: Recruiting, Estimated PCD: 2024-02-07
Clinical trial
Phase I/II Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-05-25
Clinical trial
A Phase 1 Clinical Study to Evaluate IMM2520 Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-03-10
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients With HER2-Expressing Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
An Open-label, Multicenter, First-in-human Dose-escalation and Cohort Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMM2902 in the Treatment of HER2-expressing Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase III Randomized, Open-label, Multicenter Clinical Study of IMM01 (Timdarpacept) in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-06-01